The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
Status:
Recruiting
Trial end date:
2030-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the value of molecular residual disease (MRD)
monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer
are:
- prognostic value of baseline MRD;
- the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood
derived from participants will be obtained for MRD test before adjuvant chemotherapy
initiation and at the first imaging assessment after chemotherapy.